AI assistant
BIOLIFE SOLUTIONS INC — Director's Dealing 2021
May 18, 2021
32106_dirs_2021-05-17_2d7529f9-119a-48e2-ae65-07595a12c654.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOLIFE SOLUTIONS INC (BLFS)
CIK: 0000834365
Period of Report: 2021-05-13
Reporting Person: Berard Todd (Chief Marketing Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-13 | Common Stock | M | 6160 | $1.64 | Acquired | 85726 | Direct |
| 2021-05-13 | Common Stock | S | 6160 | $29.52 | Disposed | 79566 | Direct |
| 2021-05-14 | Common Stock | M | 6160 | $1.64 | Acquired | 85726 | Direct |
| 2021-05-14 | Common Stock | S | 6160 | $29.68 | Disposed | 79566 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-05-13 | Stock Option (Right to Buy) | $1.64 | M | 6160 | Disposed | 2021-12-20 | Common Stock (6160) | Direct |
| 2021-05-14 | Stock Option (Right to Buy) | $1.64 | M | 6160 | Disposed | 2021-12-20 | Common Stock (6160) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 12, 2020.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.02 to $30.70 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.90 to $30.12 per share, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4: On December 20, 2016, the reporting person was granted an option to purchase 123,209 shares of common stock which vested in two equal annual installments on March 8, 2018 and March 8, 2019.